Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

BCC Research LLC

"BCC Research examines how AI is speeding up trait discovery, improving seed development, predicting crop performance and supporting faster commercialization of GM crops."

Boston, June 12, 2026 (GLOBE NEWSWIRE) -- Artificial intelligence is fundamentally transforming the genetically modified foods industry, accelerating innovation cycles and reshaping how agricultural companies address mounting global food security challenges, according to BCC Research's new AI Impact on Genetically Modified Foods Market - BCC Pulse Report. The analysis examines how AI technologies are revolutionizing crop development, regulatory compliance, and supply chain management across the global GM agriculture sector.

Key Findings

• Accelerated Innovation Cycles: AI-driven genomic selection models are reducing GM crop development timelines by combining DNA markers with environmental data to predict performance across diverse climatic conditions, addressing traditional breeding method limitations. • Strategic Investment Surge: Major agricultural companies are treating AI as a strategic pillar, with Bayer committing an additional $1.52 billion to its Leaps venture investment arm in 2022 specifically for breakthrough innovations in life sciences and agriculture. • Supply Chain Transformation: Blockchain-enabled AI systems are enhancing traceability throughout GM supply chains, while computer vision technologies enable hybrid purity testing and off-type seed detection with unprecedented accuracy. • Climate Resilience Focus: Machine learning applications for pest evolution simulation and disease outbreak forecasting are addressing rapidly evolving agricultural threats that overcome existing genetic resistance in GM crops. • Precision Agriculture Integration: AI-powered precision spraying technologies are reducing herbicide usage while supporting complex multi-trait designs that stack herbicide tolerance, insect resistance, and drought tolerance capabilities. • Industry Leadership Consolidation: Key players including Bayer, Syngenta, Corteva, BASF, and LongPing High-Tech are leveraging AI platforms, with Corteva's Breeding Analytics Engine utilizing advanced algorithms to evaluate millions of genetic combinations simultaneously.

Strategic Implications

The convergence of AI and genetic modification technologies represents a paradigm shift in addressing global food security challenges. Rising food demand and climate uncertainty are driving unprecedented need for resilient crops, while traditional development methods struggle with the complexity of multi-trait designs and climate prediction. AI is emerging as the critical enabler, reducing development costs while accelerating innovation in GM trait discovery. Government funding expansion across major GM-producing regions including the U.S., Brazil, Argentina, China, and India is supporting AI-enabled agricultural research, creating favorable conditions for sustained investment. Companies are scaling GM programs through AI-enabled phenotyping systems, with LongPing High-Tech's maize initiatives exemplifying this trend.

Story Continues

Investment Considerations

The AI-GM foods intersection presents compelling opportunities for investors focused on agricultural technology and food security solutions. Companies with established AI capabilities and strong R&D pipelines are best positioned to capture market share as regulatory frameworks adapt to accelerated innovation cycles. Key investment themes include genomic selection platforms, precision agriculture technologies, and supply chain traceability solutions. However, investors should monitor regulatory bottlenecks and evolving biosafety assessment requirements that could impact commercialization timelines. Strategic partnerships between established agricultural companies and AI technology providers represent particularly attractive value creation opportunities.

About the Report

The report provides comprehensive analysis of AI's transformative impact on the GM foods industry, examining technology adoption patterns, investment trends, competitive dynamics, and regulatory developments. AI Impact on Genetically Modified Foods Market - BCC Pulse Report delivers strategic intelligence for stakeholders navigating this rapidly evolving sector.

About BCC Research BCC Research provides objective, unbiased measurement and assessment of market opportunities with detailed market research reports. Our experienced industry analysts assess growth trends, identify and evaluate new and changing market opportunities, and provide critical information and innovative decision support tools to help inform the strategic decision-making process.

For media inquiries, email press@bccresearch.com or visit our media page for access to our market research library. Any data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

(Bloomberg) -- Bayer AG shares are facing a make-or-break few weeks, with two upcoming court developments key to stemming a more than $60 billion wipeout in market value since the German company’s ill-fated purchase of Monsanto eight years ago.

Most Read from Bloomberg

SpaceX IPO Raises $75 Billion in Biggest Debut of All Time Xbox Plans Significant Layoffs as New CEO Plans Overhaul Trump Insists Iran Deal Is Close After Scrapping New Strikes Trump Vows New Attacks on Iran, Threatens Key Energy Targets UAE and Iran Meet Face-to-Face to Try to Deescalate Tensions

Investors are awaiting a US Supreme Court ruling on Bayer’s bid to stop tens of thousands of lawsuits claiming that Monsanto’s Roundup herbicide should have been labeled as a cancer risk. Around the same time, a fairness hearing over a separate $7.25 billion class-action settlement to resolve current and future cancer lawsuits over Roundup is also scheduled.

If most of the litigation is resolved, the stock would become more investable and could rise to €50, according to Jefferies analyst Michael Leuchten. In a downside scenario, with another double-digit billion-euro litigation provision and a multi-decade overhang, the shares could fall to €30, he wrote. Bayer closed at €35.79 on Thursday.

“The litigation overshadows everything,” said Markus Manns, portfolio manager at Frankfurt-based asset manager Union Investment, a Bayer investor. “Only once there is clarity on the litigation can the company develop a reliable financial plan regarding earnings growth, debt reduction and other priorities.”

A Bayer spokesperson said Monsanto has “a multipronged strategy” and is “confident but prepared” for all outcomes with regard to both the Supreme Court case and the class settlement agreement.

The Supreme Court is expected to rule by early July. Justices heard arguments in April, weighing a $1.25 million jury verdict won by a Missouri man who blamed Roundup for his non-Hodgkin lymphoma. Bayer contends that since US regulators didn’t require a cancer warning, federal law bars the Missouri suit and others like it.

A favorable outcome in the Supreme Court will help to ease Bayer’s legal issues because it would wipe out failure-to-warn theories that have provided the basis for big-dollar verdicts in Roundup cases. The April hearing was less positive for Bayer than some had expected, and the shares have been trending lower since then.

Listen: Bayer’s Cancer Claims Roundup at US Supreme Court: BI Podcast

Still, analysts at Bank of America Corp. recently cited a legal expert who sees a 70% probability that the court rules in Bayer’s favor. And Barclays Plc analyst Charles Pitman-King expects the company “to make significant progress in resolving the majority of its outstanding litigation overhang,” helping it to unlock its fundamental valuation.

Story Continues

Settlement Hearing

The other key milestone is over Bayer’s $7.25 billion proposal to settle thousands of current and future Roundup claims. A fairness hearing is scheduled for July 9 in state court in Missouri, but opponents of the settlement have asked for a transfer to San Francisco to get the case in front of a federal judge who has already publicly noted the deal’s flaws. Bayer objected the move and said it’s confident it has good arguments for the case to be returned to Missouri’s courts.

Potential changes to the location and, therefore, timing of that decision have also unsettled investors, who are keen to move on from the Monsanto saga.

Bayer investor Manns thinks the company is likely to get its way in at least one of the cases. “I expect that a majority, likely more than 80%, of plaintiffs will support the proposal, as the settlement terms are very favorable,” he said.

“However, if both efforts fail, then we would be looking at a significant, possibly catastrophic, setback for Bayer. The long-term financial uncertainty would remain. Investors would never know when the next €5 billion settlement payment might be required.”

Bayer has already paid more than $11 billion in Roundup settlements and still faces more than 65,000 current suits blaming its active ingredient, glyphosate, for causing non-Hodgkin lymphoma, according to securities filings. The shares are down more than 60% since the company completed the $63 billion Monsanto deal.

“Bayer’s hubristic purchase of Monsanto, with what must be viewed as woeful due diligence, has been the ultimate corporate nightmare that keeps on giving,” said Ketan Patel, a fund manager at the family office Whitefriars, which doesn’t own Bayer shares.

Patel sees risks to Bayer around both rulings, noting that a Supreme Court decision against the company “could open the floodgates in every State where Roundup was sold, and where the rules surrounding labeling are interpreted differently from State to State.”

Many are more positive on the company’s prospects. The shares have 16 buy ratings among 21 analysts tracked by Bloomberg, with an average price target that suggests more than 40% upside. For Barclays’ Pitman-King, who rates Bayer overweight, the resolution of litigation could also open the door to a possible consumer health separation in future, helping the stock achieve its estimated €53 to €60 sum-of-the-parts valuation.

Still, even if the two upcoming cases go Bayer’s way, the company has other legal battles to contend with. While Monsanto stopped supplying toxic chemicals known as polychlorinated biphenyls — or PCBs — to customers for use in their products decades ago, the company has been sued by state and local governments, school districts and individuals.

Bayer has already agreed to pay almost $2 billion in settlements in PCB cases, and potentially faces billions of dollars in exposure from a growing number of lawsuits over PCB products filed by state and local governments, school districts and individuals. It is pursuing a strategy to recoup some of its litigation costs from other companies, such as General Electric Co., that were large users of the chemicals.

Read: Bayer Faces Billions in Payouts for Decades-Old Toxic Mess

“The lesson of the last decade I’d draw is: there’s always someone in the US who wants to sue Monsanto,” said Berenberg’s Sebastian Bray. “A Supreme Court victory would be a great way of protecting Bayer, but it probably wouldn’t solve absolutely everything.”

--With assistance from Jef Feeley.

Most Read from Bloomberg Businessweek

Gen Z’s Latest Career Flex: A Boardroom Seat How a Tiny British Island Fell Into an International Gambling Scandal The Bankrupting of a Mobile Home Billionaire Ice Cream Not Decadent Enough for You? Dip It in Butter SpaceX IPO Demands Trust in Musk’s Entangled Empire

©2026 Bloomberg L.P.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Bayer BAYRY announced that the European Medicines Agency (EMA) has validated the marketing authorization application for its investigational, once-daily, oral Factor XIa inhibitor, asundexian, for the prevention of ischemic stroke in adults after a non-cardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). This marks the completion of the regulatory application submission process and the beginning of the EMA’s centralized review procedure.

Bayer noted that stroke is an increasing public health challenge, affecting approximately 10 million people in Europe living with its long-term consequences, while more than one million new cases are reported each year. BAYRY added that stroke remains the world's and Europe's second-leading cause of death, placing a substantial burden on healthcare systems, with global costs estimated at $891 billion annually.

Shares of Bayer have lost 6.1% year to date against the industry’s 4.8% growth.Zacks Investment Research

Image Source: Zacks Investment Research

BAYRY’s EU Filing for Asundexian Supported by Phase III Data

Bayer’s marketing application for asundexian to the EMA is supported by encouraging data from the phase III OCEANIC-STROKE study. The study investigated the efficacy and safety of asundexian 50 mg compared to placebo for the prevention of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk TIA in combination with antiplatelet therapy. It enrolled 12,327 patients worldwide.

The primary efficacy endpoint was time to ischemic stroke, and the primary safety endpoint was major bleeding.

Bayer reported that in the OCEANIC-STROKE study, asundexian significantly reduced ischemic stroke by 26% in patients after a non-cardioembolic ischemic stroke or high-risk TIA, compared to placebo, both in combination with antiplatelet therapy, with no increase in the risk of International Society on Thrombosis and Hemostasis major bleeding.

The benefit was consistent across all major patient subgroups, regardless of age, sex, stroke subtype, stroke severity, or background antiplatelet regimen. Asundexian is viewed as a potential blockbuster opportunity in a market where the risk of recurrent stroke remains high.

Bayer is also pursuing broader global regulatory approvals for asundexian. Last month, the FDA accepted BAYRY’s regulatory filing for asundexian to prevent ischemic stroke in patients following a non-cardioembolic ischemic stroke or TIA under its Priority Review pathway, potentially accelerating the regulatory review process in the United States. A filing for the candidate for the same indication is also currently under review in Japan.

Story Continues

In addition to the U.S. and Japan filings, China’s regulatory body also recently accepted Bayer’s marketing authorization application for the therapy to treat the above indication and granted it Priority Review designation.

Bayer Aktiengesellschaft Price and ConsensusBayer Aktiengesellschaft Price and Consensus

Bayer Aktiengesellschaft price-consensus-chart | Bayer Aktiengesellschaft Quote

BAYRY’s Zacks Rank & Other Stocks to Consider

Bayer currently carries a Zacks Rank #2 (Buy).

Some other top-ranked stocks in the biotech sector are Liquidia Corporation LQDA, Indivior Pharmaceuticals INDV and Immunocore IMCR, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 60 days, estimates for Liquidia Corporation’s 2026 EPS have increased from $1.50 to $2.97. Over the same period, EPS estimates for 2027 have also increased from $2.91 to $4.81. LQDA shares have rallied 89.2% year to date.

Liquidia Corporation’searnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.

Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen to $4.27 from $3.66. INDV shares have gained 6.1% year to date.

Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.

The estimate for Immunocore’s 2026 EPS is currently pegged at 6 cents. In the past 60 days, the estimates for its 2027 EPS have increased from 24 cents to 87 cents. IMCR shares have lost 19.6% year to date.

Immunocore’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 46.66%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Bayer Aktiengesellschaft (BAYRY) : Free Stock Analysis Report

Liquidia Corporation (LQDA) : Free Stock Analysis Report

Immunocore Holdings PLC Sponsored ADR (IMCR) : Free Stock Analysis Report

Indivior Pharmaceuticals Inc. (INDV) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Oriva Therapeutics

Oriva is developing innovative medicines for chronic gynaecological diseases and is backed by pre-seed financing from Asabys Partners’ Sabadell Asabys II fund Dr Arbat brings over 25 years’ pharma industry experience, including roles in women’s health at Bayer and Organon Oriva’s lead asset, ORV-362 – a non-hormonal, disease-modifying, first-in-class therapy for endometriosis – is already in Phase I clinical trials

BARCELONA, Spain, June 11, 2026 (GLOBE NEWSWIRE) -- Oriva Therapeutics (“Oriva”), a women’s health company developing first-in-class and best-in-class approaches to treat chronic, prevalent conditions affecting women, today announces the appointment of seasoned biotech entrepreneur Dr Agnès Arbat as Chief Executive Officer.

Dr Arbat brings more than 25 years of experience in the pharmaceutical industry, with a strong track record across clinical development, medical affairs and commercial strategy in women’s health. During her career she has played a central role in over 20 clinical studies in women’s health. She has also contributed to the successful launch of more than 10 products including Nexplanon, Xarelto and Ventavis.

She was previously Co-founder and CEO of Oxolife, a specialist biotech focused on female fertility, and before that led the Women’s Health and Cardiovascular medical team at Bayer and worked at Organon in Medical Affairs for Women’s Health.

Dr Arbat will also serve as Oriva’s Chief Medical Officer. She joins the highly-experienced senior leadership team of biochemist Cristina Balagué, PhD (Chief Scientific Officer); pharmaceutical scientist Rosa Torres Ferraz, PhD (Head of Medical Affairs & Regulatory); biotech entrepreneur and scientist Ljudmila Katchan, PhD (Head of Operations) and clinical trials expert Marta Llorens (Head of Clinical Operations), with the company’s financial strategy overseen by Roger Juanpere (Financial Manager).

Dr Agnès Arbat, Chief Executive Officer, Oriva Therapeutics, said: “Oriva’s assets have the potential to deliver best-in-class treatments for women worldwide suffering from common, painful and debilitating gynaecological conditions – thus addressing clear and significant unmet medical needs. As CEO and CMO, I look forward to working with the Company’s expert senior leadership team to progress its fantastic programmes through development. With clinical activity already underway and strong backing from Asabys Partners, we are well positioned to execute and deliver meaningful progress for patients.”

Clara Campàs, Co-Founder and Managing Partner at Asabys Partners, said: “Agnès’ deep scientific expertise in women’s health and her strong track record of strategic leadership makes her exceptionally well qualified to lead Oriva as it advances its programmes and accelerates through its next phase of growth.”

Story Continues

Oriva was founded earlier this year with the support of Asabys Partners and is now advancing its clinical-stage pipeline, which includes two advanced assets. Its lead asset is ORV-362, a first-in-class, non-hormonal, disease-modifying therapy for endometriosis, which affects about 10% of women of reproductive age worldwide.

Endometrioisis – the growth of tissue similar to the lining of the uterus in other parts of the body, usually within the pelvis – is a painful condition that can negatively affect fertility. Despite its prevalence and significant impact on women, only limited treatment options are currently available. None can address the underlying pathology of endometriosis while preserving fertility.

ORV-362 has been designed as a disease-modifying treatment that does not interfere with conception. It has already demonstrated a favourable safety profile in early-stage clinical trials. The programme advanced into Phase I clinical development in healthy women in January 2026, and initial clinical readouts are expected by the end of this year.

Oriva’s second programme, ORV-499, is focused on the treatment of uterine fibroids, the most common type of benign gynaecological tumour. ORV-499 is expected to enter Phase I clinical trials in Q1 2027. Both assets target well-validated therapeutic pathways and leverage novel chemistry, providing clear differentiation from existing treatment options and other drugs in development.

Dr Arbat holds a medical degree from the Autonomous University of Barcelona with a specialty in Clinical Pharmacology and completed the General Management Programme at IESE Business School. She is a guest professor and mentor for the Master's in Pharmaceutical Industry and Biotechnology programme at Universitat Pompeu Fabra (UPF) and Universitat Internacional de Catalunya (UIC). Last year, she was awarded the EU Women Innovators Prize at the European Innovation Council (EIC) Summit, the Catalonia Health Innovation Award, and the European Investment Bank Group prize for Advancing Innovation in Women's Health.

For more information contact:

Optimum Strategic Communications Mary Clark / Stephen Adams / Katie Flint / Aoife Minihan T: +44 208 078 4357 E: oriva@optimumcomms.com

About Oriva Therapeutics Oriva Therapeutics is a clinical-stage women’s health biotechnology company focused on the development of first-in-class and best-in-class therapies for chronic, prevalent gynecological diseases with high unmet medical need. Based in Barcelona, the company has been created to advance innovative and disease-modifying approaches that aim to improve both clinical outcomes and quality of life for women. Oriva Therapeutics’ pipeline is built around two advanced programmes in endometriosis and uterine fibroids, leveraging novel chemistry targeting validated biological pathways and differentiated from existing treatment options. The company was seeded by Sabadell Asabys II, a fund managed by Asabys Partners, and is backed by assets originating from Oncostellae and Medibiofarma.

About Asabys Partners Asabys Partners is a Barcelona-based venture capital firm focused on innovation in healthcare and life sciences, including biopharma, medical technology, and digital health. Founded in 2018 by Josep Ll. Sanfeliu and Clara Campàs, the firm is backed by Alantra and supported by Banc Sabadell as anchor investor. Asabys aims to support highly innovative and transformative technologies that address unmet medical needs. The firm manages over €400 million in assets and 24 portfolio companies. Asabys positions itself not only as an investor but as an active and collaborative partner to its portfolio companies, with the goal of translating disruptive science into meaningful outcomes for patients. The investment in the company comes from its vehicles Sabadell Asabys Health Innovation Investments II, FCR, and Sabadell Asabys Health Innovation Investments 2B, SCR SA.

www.asabys.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors

Proceeds will support clinical advancement of lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD)

SAN FRANCISCO, June 10, 2026--(BUSINESS WIRE)--SonoThera, a biotechnology company developing next-generation genetic medicines to address the root causes of disease, today announced the closing of an oversubscribed $125 million Series B financing round to advance its lead programs in Duchenne muscular dystrophy (DMD) and autosomal dominant polycystic kidney disease (ADPKD) into the clinic and expand its pipeline of targeted, redosable genetic medicines.

The financing was led by Vida Ventures, with participation from ARK Invest, CureDuchenne Ventures, Leaps by Bayer, Otsuka Pharmaceutical, SymBiosis, UCB Ventures SA, Vivo Capital, and existing investors ARCH Venture Partners, Alexandria Venture Investments, Duquesne Family Office, Illumina Ventures, Johnson & Johnson, through its corporate venture capital organization, Johnson & Johnson Innovation – JJDC, Inc., Medical Excellence Capital, RA Capital, and Vertex Ventures HC.

In connection with the financing, Rajul Jain, M.D., Managing Director at Vida Ventures, and Rakhshita Dhar, M.S., Vice President & Head, Healthcare Venture Investments at Leaps by Bayer, have joined SonoThera's Board of Directors.

Proceeds from the financing will advance SonoThera's lead programs in DMD and ADPKD into the clinic, expand its pipeline across multiple organ systems, and further scale its proprietary platform technologies designed to enable safe, targeted, and repeatable delivery of genetic medicines. The oversubscribed financing follows significant preclinical progress demonstrating targeted delivery across multiple tissues and successful delivery of both large DNA and RNA payloads, underscoring strong investor conviction in SonoThera's platform and pipeline.

SonoThera's platform combines RIPPLE™, a proprietary ultrasound-mediated delivery technology, with PORE™, a payload engineering platform that supports DNA and RNA therapeutics, gene editing, and gene silencing approaches. Anchored by these technologies, the company is developing targeted, redosable genetic medicines designed to address key limitations of conventional gene therapies, including delivery challenges, payload size constraints, immune responses, safety events, and the inability to redose.

Story Continues

"We are grateful to have the support of this exceptional group of new and existing investors who share our vision of expanding the potential of genetic medicines," said Kenneth Greenberg, Ph.D., Co-Founder and Chief Executive Officer, SonoThera. "Despite remarkable scientific progress, many diseases remain beyond the reach of today's genetic medicines. We founded SonoThera to take a fundamentally different approach, with a platform designed to broaden the therapeutic possibilities of the field. We believe our technology has the potential to expand the range of diseases addressable by genetic medicines while enabling more precise, durable, safer, and repeatable therapies for patients."

"We at Vida have a long history of investing in and developing genetic medicines, some of which are now used to treat patients across the globe. We believe SonoThera, with its RIPPLE™ delivery and PORE™ payload engineering technologies, has the potential to unlock opportunities in diseases with significant unmet need that have been previously inaccessible to other genetic medicine approaches," said Rajul Jain, M.D., Managing Director at Vida Ventures. "We have been deeply impressed by SonoThera's scientific rigor, pace of execution, and vision, and we are excited to support the company as it advances its first programs into the clinic."

"SonoThera has made impressive progress since its founding and continues to demonstrate the potential of its approach to genetic medicine," said Steven Gillis, Ph.D., Managing Director at ARCH Venture Partners. "The team has built a strong foundation, generated compelling preclinical data, and assembled an outstanding group of investors and partners. We are excited to continue supporting the company as it advances toward the clinic."

The company has demonstrated targeted delivery and expression across multiple tissues, including skeletal muscle, heart, liver, kidney, adipose, and brain, as well as delivery of large genetic payloads such as full-length dystrophin for DMD and RNA-based payloads for gene silencing applications in preclinical studies. SonoThera expects to initiate its first clinical trial in DMD in 2027.

"At CureDuchenne, we are committed to supporting innovative approaches that have the potential to transform the lives of individuals living with Duchenne muscular dystrophy," said Debra Miller, Founder and CEO of CureDuchenne. "SonoThera's differentiated nonviral platform has the potential to address important challenges in gene delivery and bring treatments to families who have been left waiting. We are proud to support the company's next phase of growth and clinical development."

SonoThera's approach leverages widely available, FDA-cleared diagnostic ultrasound systems and commercial ultrasound contrast agents approved for diagnostic uses, enabling an investigational, noninvasive outpatient procedure that can be performed in approximately one hour or less.

About SonoThera

SonoThera is developing an ultrasound-mediated nonviral genetic medicine platform designed to deliver the next generation of safe, targeted, and redosable genetic medicines. By integrating proprietary RIPPLE™ ultrasound delivery with PORE™ payload engineering, the company is advancing a broad range of genetic medicine approaches, including DNA and RNA therapeutics, gene editing, and gene silencing. SonoThera's platform is designed to enable precise, durable gene expression across multiple tissues while addressing key limitations associated with viral delivery approaches. The company is advancing a pipeline of genetic medicines for serious diseases, including Duchenne muscular dystrophy and autosomal dominant polycystic kidney disease. SonoThera is headquartered in South San Francisco, California. For more information, visit www.sonothera.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260610731032/en/

Contacts

Media Contact

Kimberly Ha KKH Advisors 917-291-5744 kimberly.ha@kkhadvisors.com

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Nxera Pharma

Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. ("Nxera" or the "Company")　announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded into an international ecosystem comprising numerous pharmaceutical companies, biotechnology companies, technology companies and academic institutions, including Bristol Myers Squibb, Novo Nordisk, Bayer and Roche.

OpenFold's mission is provide researchers from academia and industry with access to powerful AI-enabled tools to create the medicines of tomorrow, to accelerate basic biological research, and bring new cures to market that would be impossible to discover without AI.

Nxera's participation in OpenFold is aligned with the Company's policy to enhance R&D productivity and business efficiency through the use of AI technologies, as presented at the Company's 36th Ordinary General Meeting of Shareholders held on 25 March 2026. Nxera's proprietary NxWave™ platform combines the Company's long-standing expertise in GPCR structure-based drug discovery, proprietary data, computational chemistry and AI-enabled approaches to advance drug discovery research.

Through its participation in the OpenFold Consortium, Nxera aims to:

Create synergies with Nxera's AI-driven computational chemistry and quantum-inspired biophysical approaches to accelerate progress from target validation and discovery to clinical development with highly differentiated and optimized candidates Continuously use and evaluate state-of-the-art open-source structural prediction models, including OpenFold and OpenFold3-preview Conduct GPCR target-focused performance evaluations and benchmarking through its computational chemistry team Contribute to future research and development directions through consortium governance meetings and receive technical support

Nxera is participating in the consortium as a user of its open-source tools and is not required to contribute any proprietary data or intellectual property to the consortium.

Patrik Foerch, Nxera's Chief Scientific Officer and President of Nxera Pharma UK, commented: "Our participation in the OpenFold Consortium is highly aligned with the core design philosophy of the NxWave™ platform: the integration of structural biology, computational chemistry and AI. Access to an ecosystem that advances open-source AI drug discovery alongside world-class pharmaceutical companies and research institutions will further strengthen our AI-enabled drug discovery capabilities for GPCRs, a medically important and challenging target class. This initiative forms part of our broader strategy to improve R&D productivity and advance rapidly from target to clinical development with highly differentiated and optimized molecules, as we work towards achieving our 2030 vision."

Story Continues

–END–

About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. The Company has built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high-value, large and growing market and those in the broader APAC region. In addition, the Company is advancing an extensive pipeline internally and in partnership with leading pharma and biotech companies powered by its unique NxWave™ GPCR structure-based drug discovery platform. Nxera Pharma operates at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565).

For more information, please visit www.nxera.life LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma

Enquiries:

Nxera – Media and Investor Relations Shinya Tsuzuki, VP, Head of Investor Relations Maya Bennison, Communications Manager +81 (0)3 5210 3399 | +44 (0)1223 949390 |IR@Nxera.life

MEDiSTRAVA (for International Media) Mark Swallow, Frazer Hall, Erica Hollingsworth +44 (0)203 928 6900 | Nxera@medistrava.com

Forward-looking statements This press release contains forward-looking statements, including statements about the discovery, development, and commercialization of products. Various risks may cause Nxera Pharma Group's actual results to differ materially from those expressed or implied by the forward looking statements, including: adverse results in clinical development programs; failure to obtain patent protection for inventions; commercial limitations imposed by patents owned or controlled by third parties; dependence upon strategic alliance partners to develop and commercialize products and services; difficulties or delays in obtaining regulatory approvals to market products and services resulting from development efforts; the requirement for substantial funding to conduct research and development and to expand commercialization activities; and product initiatives by competitors. As a result of these factors, prospective investors are cautioned not to rely on any forward-looking statements. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View Comments

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

WHIPPANY, N.J., 09. Juni 2026--(BUSINESS WIRE)--Bayer hat heute bekannt gegeben, dass Dr. Jost Reinhard zum Präsidenten der Radiologie-Branche innerhalb der Pharmazeutischen Division von Bayer ernannt wurde, ab dem 1. August 2026. In seiner neuen Funktion wird er sich an Stefan Oelrich, Mitglied des Vorstands von Bayer AG und Präsident der Pharmazeutischen Division, berichten. Reinhard folgt Nelson Ambrogio, der im Mai 2026 zum Präsidenten der Bayer U.S. Pharmaceuticals wurde.

"Mit einer überzeugenden Leistung in den letzten Jahren und einem klaren strategischen Fokus ist Radiologie ein wichtiger Pfeiler des Wachstumsagendas von Bayer", sagte Stefan Oelrich, Mitglied des Vorstands von Bayer AG und Präsident der Pharmazeutischen Division. "Jost Reinhard bringt eine starke Kombination aus wissenschaftlicher Expertise, strategischem Blickwinkel und globaler Führungserfahrung und ich bin sicher, dass er den nächsten Schritt der Innovation und des Wachstums für diese Branche erfolgreich vorantreiben wird."

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Investoren, die sich für Large Cap Pharmaceuticals interessieren, haben wahrscheinlich sowohl Bayer Aktiengesellschaft (BAYRY) als auch Roche Holding AG (RHHBY) kennengelernt. Aber welche dieser beiden Aktien bietet den Investoren derzeit das bessere Wertangebot? Lassen Sie uns genauer hinschauen.

Wir haben festgestellt, dass die beste Möglichkeit, großartige Wertmöglichkeiten zu entdecken, darin besteht, eine starke Zacks-Rangliste mit einer guten Bewertung in der Werte-Kategorie unseres Style-Scores-Systems zu kombinieren. Die bewährte Zacks-Rangliste betont Unternehmen mit positiven Revisionstrends für die Earnings-Prognose und unsere Style-Scores hervorheben Aktien mit bestimmten Merkmalen.

Derzeit hat Bayer Aktiengesellschaft einen Zacks-Rang von #2 (Kaufen), während Roche Holding AG einen Zacks-Rang von #3 (Halten) hat. Die Investoren sollten sich sicher fühlen, dass BAYRY wahrscheinlich eine stärkere Verbesserung seiner Earnings-Prognose als RHHBY in letzter Zeit erlebt hat. Aber dies ist nur ein Teil des Bildes für Wertinvestoren.

Wertinvestoren sind auch an einer Reihe bewährter Bewertungsmaßstäbe interessiert, die helfen, zu zeigen, wenn eine Aktie bei ihrem aktuellen Stückpreis unterbewertet ist.

Die Werte-Kategorie unseres Style-Scores-Systems identifiziert unterbewertete Unternehmen, indem sie verschiedene Schlüsselmaßstäbe betrachtet. Dazu gehören der lange bevorzugte KGV-Wert, das KGV-Verhältnis, der EBIT-Yield, der Cashflow pro Aktie und eine Vielzahl anderer Grundlagen, die uns helfen, den fairen Wert eines Unternehmens zu bestimmen.

BAYRY hat derzeit ein Vorwärts-KGV von 8,27, während RHHBY ein Vorwärts-KGV von 15,62 hat. Wir stellen auch fest, dass BAYRY ein PEG-Verhältnis von 3,31 hat. Dieses Maß wird ähnlich wie das berühmte KGV verwendet, aber das PEG-Verhältnis nimmt auch die erwartete Wachstumsrate der Aktie in den Blick. RHHBY hat derzeit ein PEG-Verhältnis von 4,23.

Ein weiteres bemerkenswertes Bewertungsmaß für BAYRY ist sein KGV-Verhältnis von 1,37. Die Investoren verwenden das KGV-Verhältnis, um den Marktwert einer Aktie gegenüber ihrem Buchwert zu betrachten, der als Gesamtbetriebsvermögen minus Gesamtverbindlichkeiten definiert ist. Im Vergleich dazu hat RHHBY ein KGV-Verhältnis von 7,17.

Basierend auf diesen Maßstäben und vielen mehr hält BAYRY eine Werte-Bewertung von A, während RHHBY eine Werte-Bewertung von C hat.

BAYRY erlebt derzeit eine verbesserte Earnings-Prognose, was es in unserem Zacks-Rangmodell hervorheben lässt. Und basierend auf den oben genannten Bewertungsmaßstäben fühlen wir, dass BAYRY wahrscheinlich die überlegene Wertoption ist.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Basel, Schweiz & Whippany, N.J., 8. Juni 2026--(BUSINESS WIRE)--Bayer hat heute eine Reihe von Führungswechseln innerhalb seiner Consumer Health-Division bekannt gegeben, um das Wachstum zu beschleunigen, die kommerzielle Umsetzung zu stärken und die Entscheidungsgeschwindigkeit weiter zu verbessern. Diese Änderungen spiegeln das Unternehmensengagement wider, kontinuierlich anpassungs- und fortschrittsorientiert zu sein, um seine Road to Billions-Strategie zu unterstützen, mit der es Milliarden von Menschen dabei helfen will, ein gesünderes Leben zu führen.

Haftungsausschluss: Der Text wurde mit Hilfe einer KI zusammengefasst und übersetzt. Für Aussagen aus dem Originaltext wird keine Haftung übernommen!

Finerenone, ein Medikament von Bayer, hat in einer Studie gezeigt, dass es bei Patienten mit chronischer Nierenkrankheit (CKD) die Funktion der Nieren verbessern kann. Die Ergebnisse der Studie wurden kürzlich im New England Journal of Medicine veröffentlicht. In der Studie wurden 5.884 Patienten mit CKD teilgenommen, die entweder Finerenone oder ein Placebo erhielten. Die Ergebnisse zeigten, dass Finerenone die Funktion der Nieren um etwa 15% verbessern konnte. Dies ist ein wichtiger Schritt für die Behandlung von CKD, da es den Patienten helfen kann, ihre Nierenfunktion zu erhalten und möglicherweise sogar wiederherzustellen. Bayer hat bereits angekündigt, dass es Finerenone in Zukunft auch für andere Indikationen verwenden wird, wie zum Beispiel bei Herzinsuffizienz.